Pharmaceutical Business review

CellaVision and Kitron sign manufacturing agreement

The agreement spans for two years and involves manufacturing of CellaVision’s analysis instruments of a worth of around SEK25 million annually. The new agreement will replace the previous agreement from 2005 and is signed in relation to the restructuring of Kitron and the company’s manufacturing move from Flen to Karlskoga. The cooperation involves manufacturing of the analysis instrument CellaVision DM96 and further development of the product’s optics and optronics.

Yvonne Martensson, CEO of CellaVision, said: “Extensive experience, specialization, and a continuous strive to improve are qualities that make Kitron a partner who complements our core competences.”